Information Provided By: 
Fly News Breaks for March 20, 2018
SAGE, MRNS
Mar 20, 2018 | 05:56 EDT
Mizuho analyst Difei Yang last night initiated Marinus Pharmaceuticals with a Buy rating and $13 price target. The company, following in the footsteps of Sage Therapeutics (SAGE), is developing a similar molecule in Ganaxolone with potential in multiple central nervous system indications including postpartum depression, Yang tells investors in a research note. The analyst sees the recent positive data from Sage in postpartum depression and major depressive disorder as positive read-throughs for Marinus.
News For MRNS;SAGE From the Last 2 Days
There are no results for your query MRNS;SAGE
